To compare the clinical outcome of topical recombinant human epidermal growth factor and conventional saline dressing in management of diabetic foot ulcers - a randomised controlled trial

Effect of topical recombinant human epidermal growth factor on wound healing in diabetic foot ulcers- randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/068922

Enrollment

Registered

2024-06-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Application of Recombinant human epidermal growth factor in diabetic foot ulcers: To apply hEGF over diabetic foot ulcers and observing the wound healing with reduction in size of the w

Eligibility

Inclusion criteria

Inclusion criteria: Diabetic foot ulcer patients

Exclusion criteria

Exclusion criteria: Diabetic ulcer with gangrenous lesion and or involving underlying boneUncontrolled diabetes patients 3.Patient with hypersensitivity reactions to hEGF gel (redness, itching,Urticarial lesion, blebs) 4.Chronic non healing ulcers due to other etiologies

Design outcomes

Primary

Measure	Time frame
Mean wound size reduction, granulation, duration of hospital stayTimepoint: Base day of debridement and at day 7, day 14 and day 21	—

Secondary

Measure	Time frame
Any allergic reactions towards hEGF applicationTimepoint: Base day of debridement & at day 7, day 14 & day 21	—

Countries

India

Contacts

Public ContactDr Ravichandran

Aarupadai veedu medical College and hospital

general.surgery@avmc.edu.in9585528583

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026